Skip to main content
AIMD
NASDAQ Life Sciences

Major Shareholder Cedes Voting Control, Updates Stake After Sale

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$2
Mkt Cap
$13.965M
52W Low
$1.61
52W High
$4.5
52W Position info
24% above low
Off High info
56% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

AIMD sits 24% above its 52-week low of $1.61 on light trading volume (0.4× avg).

Summary

Taiwan Carbon Nano Technology Corporation (TCNT), a significant shareholder of Ainos, Inc., updated its Schedule 13D to disclose a new voting agreement ceding control of its shares to Ainos KY, alongside a recent sale of common stock.


Key Events · Ownership and Investor Activity · AIMD

  • Major Shareholder Cedes Voting Control

    Taiwan Carbon Nano Technology Corporation (TCNT), holding 13.62% of Ainos, Inc., entered into a voting agreement on January 1, 2026, granting Ainos KY sole discretion over how its shares will be voted.

  • Stake Reduced After Stock Sale

    TCNT sold 46,000 shares of common stock on January 28, 2026, for general operating purposes, reducing its aggregate ownership to 989,925 shares, representing 13.62% of the company. This sale was previously reported in a Form 4 on January 30, 2026.


Analysis · AIMD · Life Sciences

This Schedule 13D/A filing reveals two key developments. Firstly, Taiwan Carbon Nano Technology Corporation (TCNT) has entered into a voting agreement with Ainos KY, effective January 1, 2026, granting Ainos KY sole discretion over how TCNT's 13.62% stake in Ainos, Inc. will be voted. This represents a significant shift in corporate governance and control dynamics, centralizing voting power. Secondly, the filing confirms TCNT's sale of 46,000 shares on January 28, 2026, for general operating purposes, which was previously reported in a Form 4. The updated ownership percentage for TCNT is now 13.62%. Investors should monitor the implications of this voting agreement on future corporate decisions and shareholder influence.

At the time of this filing, AIMD was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14M. The 52-week trading range was $1.61 to $4.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AIMD - Latest Insights

AIMD
Jul 24, 2026, 12:16 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $1.39 info
Change: -$0.125 (-8%) info
Market Cap: $11.167M info
AIMD
Jul 10, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.89
Real-time Price: $1.39 info
Change: -$0.500 (-26%) info
Market Cap: $11.167M info
AIMD
May 20, 2026, 8:00 AM EDT
Source: ACCESS Newswire
Importance Score:
8
Price at Filing: $1.60
Real-time Price: $1.39 info
Change: -$0.210 (-13%) info
Market Cap: $11.167M info
AIMD
May 13, 2026, 5:15 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.85
Real-time Price: $1.39 info
Change: -$0.460 (-25%) info
Market Cap: $11.167M info
AIMD
May 13, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.85
Real-time Price: $1.39 info
Change: -$0.460 (-25%) info
Market Cap: $11.167M info